Business
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson’s disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological
About this update from Gain Therapeutics, Inc.
[{"type":"image","alt":"Gain Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Gain Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nsPBXqjXYfLs4XgIgz1iUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/71d53e58a7e975cfd00a1328d22e0699","width":150,"height":72}},"lazy":false},{"type":"text","content":"BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson’s disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria.","length":579,"tagName":"p"},{"type":"text","content":"Details of the poster are as follows:","length":37,"tagName":"p"},{"type":"text","content":"Poster Number: SHIFT 02-072","length":27,"tagName":"p"},{"type":"text","content":"Poster Title: Design of a Phase 1b Study to Evaluate the GCase-Targeting Molecule GT-02287 in GBA1-PD and Sporadic PD","length":117,"tagName":"p"},{"type":"text","content":"Presenting Author: Raffaella Pozzi, Vice President of Clinical Operations, Gain Therapeutics","length":92,"tagName":"p"},{"type":"text","content":"About GT-02287Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Addi...